| Aug 8 |
Avadel: Q2 Earnings Snapshot
|
| Aug 8 |
Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2024 Financial Results
|
| Aug 6 |
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
|
| Aug 5 |
Does Avadel (AVDL) Have the Potential to Rally 43.6% as Wall Street Analysts Expect?
|
| Aug 1 |
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2024 Financial Results on August 8
|
| Aug 1 |
Avadel announces first subject dosing in Phase III idiopathic hypersomnia trial
|
| Jul 31 |
Avadel Pharmaceuticals Announces First Patient Dosed in Phase 3 REVITALYZ™ Trial of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
|
| Jun 27 |
Avadel Pharmaceuticals to join Russell 3000 index
|
| Jun 27 |
Avadel Pharmaceuticals to Join Russell 3000® Index
|
| Jun 21 |
Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?
|
